U.S. COMPANY FILING
BIOGEN INC. — Form 10-Q filed 2025-10-30
Filing text preview
Biogen's Q3 2025 revenue rose 2.8% to $2.53B, with net income up 20.1% to $466.5M. Rare disease growth driven by SKYCLARYS and QALSODY launches. Strategic moves include Alcyone acquisition, sale of ophthalmology rights, and $1.75B notes issuance. Risks include TECFIDERA generic competition and IRA impact.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record